1. Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study
- Author
-
Chiara Costanzi, Daniele Generali, Ilaria Zangrandi, Valeria De Giuli, Fabio Malberti, Maria Rosa Cappelletti, Giancarlo Bosio, Andrea Machiavelli, Marianna Sirico, Antonio Fioravanti, Guglielmo Giannotti, Angelo Pan, Sophie Testa, Ottavia Bernocchi, Fabiola Giudici, Alessia Giossi, Erika Maria Viola, Alfredo Molteni, Marina Foramitti, Alessandro Morandini, Antonio Cuzzoli, Matteo Giorgi-Pierfranceschi, Maurizio Scaltriti, Sergio Venturini, Giulia Chiodelli, Chiara Campana, Alessia Zoncada, Luca Pianta, Laura Romanini, Rosa Angela Tira, Generali, D., Bosio, G., Malberti, F., Cuzzoli, A., Testa, S., Romanini, L., Fioravanti, A., Morandini, A., Pianta, L., Giannotti, G., Viola, E. M., Giorgi-Pierfranceschi, M., Foramitti, M., Tira, R. A., Zangrandi, I., Chiodelli, G., Machiavelli, A., Cappelletti, M. R., Giossi, A., De Giuli, V., Costanzi, C., Campana, C., Bernocchi, O., Sirico, M., Zoncada, A., Molteni, A., Venturini, S., Giudici, F., Scaltriti, M., and Pan, A.
- Subjects
0301 basic medicine ,Male ,medicine.medical_treatment ,Cohort Studies ,0302 clinical medicine ,Monoclonal ,80 and over ,030212 general & internal medicine ,Viral ,Prospective Studies ,Prospective cohort study ,Humanized ,Aged, 80 and over ,General Medicine ,Middle Aged ,Hospitalization ,Infectious Diseases ,medicine.anatomical_structure ,Treatment Outcome ,Settore SECS-S/01 - STATISTICA ,Cohort ,Female ,Case-Control Studie ,medicine.drug ,Cohort study ,Human ,Microbiology (medical) ,Adult ,medicine.medical_specialty ,Canakinumab ,030106 microbiology ,Pneumonia, Viral ,Antibodies, Monoclonal, Humanized ,Article ,Antibodies ,lcsh:Infectious and parasitic diseases ,03 medical and health sciences ,Internal medicine ,medicine ,Humans ,lcsh:RC109-216 ,Aged ,Mechanical ventilation ,Lung ,business.industry ,SARS-CoV-2 ,Case-control study ,COVID-19 ,Pneumonia ,medicine.disease ,Prospective Studie ,Case-Control Studies ,Cohort Studie ,business - Abstract
Highlights • Canakinumab is an IL-1β antibody that neutralizes the activity of IL-1β. • The effects of canakinumab in patients with COVID-19-related pneumonia were studied. • 33 patients received canakinumab and 15 received institutional standard of care. • Treatment with canakinumab rapidly restored normal oxygen status. • Canakinumab was also associated with favorable prognosis versus SoC., Objectives Canakinumab is an IL-1β antibody that neutralizes the activity of IL-1β. We studied the efficacy and safety of canakinumab in patients with moderate COVID-19-related pneumonia. Design The aim of our study was to evaluate the reduction in duration of hospitalization with adequate oxygen status. Forty-eight patients with moderate COVID-19-related pneumonia were asked to participate in the prospective case-control study; 33 patients (Cases) signed informed consent and received canakinumab (Cohort 1); 15 patients (Controls) refused to receive the experimental drug and received institutional standard of care (SoC), (Cohort 2). Results Hospital discharge within 21 days was seen in 63% of patients in Cohort 1 vs. 0% in Cohort 2 (median 14 vs 26 days, respectively; p
- Published
- 2021